Start-up Studios

As an integral component of our multi-pronged BRIDGE partnerships, Evotec has initiated and invested into selected Startup Studios in Europe and North America which are aiming to accelerate the validation and commercialization of early-stage drug discovery concepts from top-tier academic researchers.


In June 2020, Evotec announced the launch of “Autobahn-Labs”, a novel virtual incubator, together with Samsara BioCapital, a leading life sciences investment firm and KCK Ltd., a family investment fund. Based out of the San Francisco Bay Area, Autobahn-Labs has been partnering with top academic and research institutions to catalyse early-stage drug discovery and development.

Autobahn Labs logo


In March 2021, the launch of Argobio was announced. Argobio is a start-up studio dedicated to life sciences which was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, Bpifrance, the French national investment bank, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.

Argo Bio Logo Resize


In October 2022, Evotec announced the launch of Extend, a translational BRIDGE in cooperation with CDP Venture Capital Sgr and Angelini Ventures, the Corporate Venture arm of the multi-business industrial group Angelini Industries. The Milan-based joint venture is developing translational drug discovery partnerships with renowned universities and research centers in Italy.

Logo EN small
Thomas Hanke

Thomas Hanke, PhD

EVP Head of Academic Partnerships

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive knowledge at the molecular level and the matching cutting-edge technologies & platforms to translate the data into effective precision medicines.